Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.

Ther Adv Med Oncol · 2022 · PMC9761799 · PMID 36544541

Europe PMC DOI

hedged sentence

0.0070

closest p · 0.1× alpha

0.0070

boldest claim

The sentences

marginally significantp = 0.007actually significant

Plasma TMB was also a marginally significant predictive factor in univariate analysis for OS; however, higher pTMB (HR = 0.37, 95% CI: 0.18–0.76, p = 0.007) was associated with improved OS in the multivariate analysis.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.